Share:
The Liver Meeting, organised by the American Association for the Study of Liver Diseases, was held on 5-9 November 2026 in Denver, Colorado, United States of America.
Highlights in the field of chronic hepatitis B and D research: official company press releases
- Precision BioSciences announces late-breaking PBGENE-HBV data at AASLD The Liver Meeting® 2026 further demonstrating cccDNA elimination and potential to drive viral cure
- Brii Bio presents late-breaking data from its Phase 2 ENRICH and ENHANCE studies at AASLD 2026, supporting BRII-179-based priming and enrichment strategy for HBV functional cure
- Virion Therapeutics reports progress towards HBV functional cure with continued HBsAg declines in all patients and no viral rebound two plus years following a VRON-0200 prime dose, at AASLD’s The Liver Meeting® 2026
- Vir Biotechnology announces expanded Phase 2 SOLSTICE data for elebsiran and tobevibart in chronic hepatitis delta, showing deep and sustained viral suppression, and exploratory finite treatment data
- Vir Biotechnology announces primary endpoint met in pivotal Phase 3 ECLIPSE 1 trial for elebsiran and tobevibart in chronic hepatitis delta
- Assembly Biosciences to present positive Phase 1a safety, tolerability and target engagement data for ABI-6250 at AASLD The Liver Meeting® 2026
- AusperBio reports sustained functional cure up to 15 months off all HBV treatment in treatment-naïve and NA-treated patients with chronic hepatitis B
- Aligos Therapeutics presents positive data at The Liver Meeting® 2026
- GSK showcases progress in liver portfolio at AASLD 2026
Reports from HCPLive: all reports can be accessed here
Selected highlights:
- Triple therapy more than doubles HBsAg loss vs peginterferon in HBV
- Bepirovirsen functional cure durable through week 96 in chronic hepatitis B
- AZURE-1: Brelovitug responses deepen beyond week 24 in chronic hepatitis D
- Brelovitug for chronic hepatitis D: Phase 3 AZURE-1 results
- Weekly or monthly? Fitting brelovitug into hepatitis D practice
- Elebsiran plus tobevibart suppresses HDV RNA in Phase 3 ECLIPSE 1 trial
- What ECLIPSE 1 means for hepatitis delta treatment, with Nancy Reau, MD
- HCV treatment in pregnancy, With Tatyana Kushner, MD
- Is HBV really a silent disease? New patient-reported data suggests otherwise
Reports from MedPage Today: all reports can be accessed here /free registration required/
Selected highlights:
- Another drug shows potential for functional cures in chronic hepatitis B
- Bulevirtide linked to less decompensation in chronic hep D with cirrhosis
- Trial on statins for cirrhosis won’t end debate anytime soon
Reports from NATAP: all reports can be accessed here.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.